BR-122025004681-B1 - Use of Butyricicoccus and Faecalibacterium for the preparation of a composition to treat or slow the progression of degenerative mitral valve disease in a canine.

BR122025004681B1BR 122025004681 B1BR122025004681 B1BR 122025004681B1BR-122025004681-B1

Abstract

USE OF BUTYRICICOCCUS AND FAECALIBACTERIUM FOR THE PREPARATION OF A COMPOSITION TO TREATS OR SLOW THE PROGRESSION OF DEGENERATIVE MITRAL VALVE DISEASE IN A CANINE. The present invention relates to methods and compositions for diagnosing and treating degenerative mitral valve disease in a canine. In one embodiment, a diagnostic method for early-stage degenerative mitral valve disease in a canine may comprise measuring a normalized relative abundance of a biomarker selected from the group consisting of Erysipelatoclostridium, Ruminococcaceae UCG014, Butyricicoccus, Faecalibacterium, and combinations thereof, and determining that the canine has early-stage degenerative mitral valve disease if Erysipelatoclostridium has a normalized relative abundance of 0 to 0.5, Ruminococcaceae UCG014 has a normalized relative abundance of 0 to 0.1, Butyricicoccus has a normalized relative abundance of 0 to 0.1, or Faecalibacterium has a normalized relative abundance of 0 to 0.1.

Inventors

Qinghong Li

Assignees

SOCIÉTÉ DES PRODUITS NESTLÉ S.A

Dates

Publication Date: 20260310
Application Date: 20191217
Priority Date: 20181227

Claims (4)

1. Use of a probiotic selected from the group consisting of Butyricicoccus and Faecalibacterium, characterized by being for the preparation of a composition for the treatment or slowing of the progression of degenerative mitral valve disease in a canine.
2. Use, according to claim 1, characterized in that the Butyricicoccus is Butyricicoccus spp.
3. Use, according to claim 1, characterized in that the Faecalibacterium is Faecalibacterium prausnitzii.
4. Use according to claim 1, characterized in that the composition is a pet food.

Description

REFERENCE TO RELATED DEPOSIT REQUESTS [0001] This application claims priority over US provisional patent application No. 62/785,373, filed December 27, 2018, the description of which is incorporated herein by reference. BACKGROUND [0002] Canine degenerative mitral valve disease (DMVD) is characterized by slowly progressive valvular degeneration that causes mitral regurgitation and, in some dogs, congestive heart failure (CHF). Although dogs in the early stages typically have a long preclinical period, once progressed to the CHF stage, the disease advances more rapidly with a median survival time of less than 12 months. Therefore, it is of great interest to intervene in the early preclinical stage to extend the longevity of affected dogs. In recent years, a staging scheme for classifying canine DMVD has been adopted by the consensus committee established by the American College of Veterinary Internal Medicine (ACVIM). Dogs at risk of developing DMVD, but otherwise healthy, are considered stage A; dogs with a heart murmur due to mitral regurgitation, but without clinical signs of CHF, are classified as stage B; Dogs with apparent clinical signs of CHF are classified as stage C. Stage B dogs are further divided into stage B1 or B2 due to the absence or presence of cardiac remodeling. [0003] Currently, the only drug with proven efficacy against early preclinical DMVD is pimobanden, which, like any pharmaceutical drug, comes with side effects. Currently, the gold standard for diagnosing DMVD is echocardiography, which is not only expensive but also requires a highly specialized veterinary cardiologist. Therefore, effective diagnostic methods and treatments that overcome the disadvantages of current methods and treatments continue to be sought. SUMMARY [0004] This disclosure relates generally to compositions and methods for diagnosing and treating degenerative mitral valve disease in a canine. In one embodiment, a method for diagnosing early-stage degenerative mitral valve disease in a canine may comprise measuring a normalized relative abundance of a biomarker selected from the group consisting of Erysipelatoclostridium, Ruminococcaceae UCG014, Butyricicoccus, Faecalibacterium, and combinations thereof, and determining that the canine has early-stage degenerative mitral valve disease if Erysipelatoclostridium has a normalized relative abundance of 0 to 0.5, Ruminococcaceae UCG014 has a normalized relative abundance of 0 to 0.1, Butyricicoccus has a normalized relative abundance of 0 to 0.1, or Faecalibacterium has a normalized relative abundance of 0 to 0.1. [0005] In another embodiment, a method of treating or slowing the progression of degenerative mitral valve disease in a canine may comprise administering a composition to the canine, the composition comprising a probiotic selected from the group consisting of Butyricicoccus and Faecalibacterium. [0006] In another embodiment, a pet food may comprise protein, fat, carbohydrate, fiber and a probiotic selected from the group consisting of Butyricicoccus, Faecalibacterium and combinations thereof. [0007] Additional features and advantages are described in the present invention and will become apparent from the detailed description below. DETAILED DESCRIPTION Definitions [0008] As used in this disclosure and the attached claims, the singular forms "a," "an," "the," and "the" include plural references unless the context clearly indicates otherwise. Thus, for example, a reference to "a composition" or "the composition" includes two or more compositions. The term "and/or" used in the context of "X and/or Y" should be interpreted as "X" or "Y" or "X and Y." When used herein, the terms "example" and "such as," particularly when followed by a list of terms, are merely illustrative and exemplary and should not be considered exclusive or comprehensive. [0009] As used herein, the term "about" is understood to refer to numbers within a range of numerals, for example the range of -10% to +10% of the reference number, within -5% to +5% of the reference number, or in one aspect within -1% to +1% of the reference number, and in a specific aspect within -0.1% to +0.1% of the reference number. Furthermore, all numeral ranges in this document shall be understood to include all whole numbers, fractional or non-fractional, within the range. In addition, these numeral ranges shall be interpreted as supporting a claim directed to any number or subset of numbers that is within that range. For example, a disclosure of 1 to 10 should be interpreted as covering a range of 1 to 8, 3 to 7, 1 to 9, 3.6 to 4.6, 3.5 to 9.9, and so on. [0010] All percentages expressed in the present invention are by weight of the composition on a dry matter basis, except where specifically indicated otherwise. Those skilled in the art will understand that the term "on a dry matter basis" means that the concentration or percentage of an ingredient in a composition is measured or determined after the removal of a